- Tytuł:
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology May 2021 22(5):655-664
Czasopismo naukowe